Myocyte nitric oxide synthase 2 contributes to blunted beta-adrenergic response in failing human hearts by decreasing

Mark T Ziolo1, Lars S Maier, Valentino Piacentino

  • 1Department of Physiology, Loyola University Medical Center, Maywood, Ill 60153, USA.

Circulation
|March 24, 2004
PubMed
Abstract

Insights

Nitric oxide synthase-2 (NOS2) in human heart failure limits response to beta-adrenergic stimulation. Inhibiting NOS2 restores this response, suggesting NOS2 mediates beta-AR hyporesponsiveness in heart failure.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Physiology

Background:

  • Human heart failure (HF) is characterized by a diminished response to beta-adrenergic receptor (AR) stimulation.
  • The role of nitric oxide synthase-2 (NOS2) in this blunted response remains unclear.

Purpose of the Study:

  • To investigate whether NOS2 expression contributes to the loss of inotropic reserve in human HF.
  • To determine if NOS2 inhibition can restore beta-AR responsiveness in failing human hearts.

Main Methods:

  • Human failing and nonfailing hearts were obtained at transplantation.
  • Cardiac myocyte and trabeculae contractility and intracellular calcium ([Ca2+]i) transients were measured.
  • The effects of beta-AR agonist isoproterenol (ISO) and NOS2 inhibitors (aminoguanidine or L-NIL) were assessed.

Main Results:

  • In failing hearts, ISO produced minimal inotropic and lusitropic effects.
  • NOS2 inhibition significantly enhanced ISO-induced contractility and [Ca2+]i transients, approaching levels seen in nonfailing hearts.
  • NOS2 protein expression was elevated in failing hearts where inhibition had a functional effect.

Conclusions:

  • NOS2 expression significantly limits beta-AR-mediated increases in contractility and calcium handling in human HF.
  • The beta-AR hyporesponsiveness in human HF is largely mediated by nitric oxide produced via NOS2 within cardiac myocytes.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...